FDA to Decide on Ivonescimab Approval by November 14

Regulators will reach a decision on the cancer drug by mid-November following a global clinical trial.

Updated on Oct. 1, 2026 in Cancer

Isometric editorial illustration of a medical infusion bag hanging on a clinical stand, representing drug regulatory approval. — The U.S. Food and Drug Administration is set to issue a decision on the approval of ivonescimab, a new cancer drug, on November 14. AI Illustration. Upload story photo >

Live Poll

Is it better to start available treatments now rather than waiting for potential new drug approvals?

The FDA is scheduled to reach a decision on November 14, 2026, regarding the approval of the cancer treatment ivonescimab. The application seeks to provide a therapy option for patients with EGFR-mutated lung cancer who have progressed after standard treatments.

Why it matters

The potential approval represents a new treatment path for patients whose lung cancer has advanced despite using third-generation EGFR-targeted pills. The drug utilizes a dual-action mechanism to inhibit tumor growth through both PD-1 and VEGF pathways.

In the HARMONi global trial, patients receiving ivonescimab experienced a median progression-free survival of 6.8 months compared to 4.4 months for those receiving chemotherapy alone. Grade 3 or higher side effects occurred in 50.0% of the treatment arm.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products in the United States.

Summit Therapeutics

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing new therapies for cancer.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery and development of prescription medicines.

The details

Ivonescimab is an infusion-based therapy that blocks both PD-1 and VEGF to inhibit tumor development. AstraZeneca has reinforced the effort by investing $2 billion in equity into Summit Therapeutics, securing a 12% stake in the company.

May 2024: Chinese regulators approved ivonescimab for use.
January 2026: The FDA officially accepted the application for the drug.
June 2026: Data cutoff occurred for the updated HARMONi survival analysis.
September 28, 2026: Summit Therapeutics announced the $2 billion AstraZeneca investment.
November 14, 2026: The target date for the FDA to issue its regulatory decision.

Cancer
Sept. 29
AstraZeneca Filed for Lung Cancer Drug Approval
Cancer
Sept. 26
Merck and Daiichi Sankyo Withdrew Cancer Drug Bid
Cancer
Sept. 18
EGFR Mutation Linked to Higher Lung Cancer Risk

The Big Picture

This regulatory filing follows the standards established by the HARMONi global trial. The application process serves to validate the therapeutic approach tested in that research program.

If approved, patients with EGFR-mutated lung cancer may gain access to a new infusion therapy designed for cases that have resisted previous treatments. Patients and providers should discuss potential side effects, as 7.3% of trial participants experienced severe VEGF-related issues.

The takeaway

This development highlights the ongoing shift toward dual-action immunotherapies in lung cancer treatment. Patients with limited options after third-generation EGFR therapy may find a new clinical path if the treatment is approved.